Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/23742
Type
ArticleCopyright
Restricted access
Embargo date
2030-01-01
Collections
- IOC - Artigos de Periódicos [12642]
Metadata
Show full item record
AN INHIBITOR OF THE ALTERNATIVE PATHWAY OF COMPLEMENT IN SALIVA OF NEW WORLD ANOPHELINE MOSQUITOES
Author
Affilliation
National Institutes of Health. National Institute of Allergy and Infectious Diseases. Laboratory of Malaria and Vector Research. Rockville, MD, USA / Universidade de Minas Gerais. Departamento de Parasitologia. Belo Horizonte, MG, Brasil.
Universidade de Minas Gerais. Departamento de Parasitologia. Belo Horizonte, MG, Brasil.
Universidade de Minas Gerais. Departamento de Parasitologia. Belo Horizonte, MG, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Simulídeos, Oncocersose e Infecções Simpátricas: Mansonelose e Malária.Rio de Janeiro, Rj, Brasil.
National Institutes of Health. National Institute of Allergy and Infectious Diseases. Laboratory of Malaria and Vector Research. Rockville, MD, USA
National Institutes of Health. National Institute of Allergy and Infectious Diseases. Laboratory of Malaria and Vector Research. Rockville, MD, USA
Universidade de Minas Gerais. Departamento de Parasitologia. Belo Horizonte, MG, Brasil.
National Institutes of Health. National Institute of Allergy and Infectious Diseases. Laboratory of Malaria and Vector Research. Rockville, MD, USA
Universidade de Minas Gerais. Departamento de Parasitologia. Belo Horizonte, MG, Brasil.
Universidade de Minas Gerais. Departamento de Parasitologia. Belo Horizonte, MG, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Simulídeos, Oncocersose e Infecções Simpátricas: Mansonelose e Malária.Rio de Janeiro, Rj, Brasil.
National Institutes of Health. National Institute of Allergy and Infectious Diseases. Laboratory of Malaria and Vector Research. Rockville, MD, USA
National Institutes of Health. National Institute of Allergy and Infectious Diseases. Laboratory of Malaria and Vector Research. Rockville, MD, USA
Universidade de Minas Gerais. Departamento de Parasitologia. Belo Horizonte, MG, Brasil.
National Institutes of Health. National Institute of Allergy and Infectious Diseases. Laboratory of Malaria and Vector Research. Rockville, MD, USA
Abstract
The complement system present in circulating blood is an effective mechanism of host defense, responsible for the killing of pathogens and the production of potent anaphylatoxins. Inhibitors of the complement system have been described in the saliva of hematophagous arthropods that are involved in the protection of digestive tissues against complement system-mediated damage. In this study, we describe albicin, a novel inhibitor of the alternative pathway of complement from the salivary glands of the malaria vector, Anopheles albimanus The inhibitor was purified from salivary gland homogenates by reverse-phase HPLC and identified by mass spectrometry as a small (13.4-kDa) protein related to the gSG7 protein of Anopheles gambiae and Anopheles stephensi Recombinant albicin was produced in Escherichia coli and found to potently inhibit lysis of rabbit erythrocytes in assays of the alternative pathway while having no inhibitory effect on the classical or lectin pathways. Albicin also inhibited the deposition of complement components on agarose-coated plates, although it could not remove previously bound components. Antisera produced against recombinant albicin recognized both the native and recombinant inhibitors and also blocked their activities in in vitro assays. Using surface plasmon resonance and enzymatic assays, we found that albicin binds and stabilizes the C3-convertase complex (C3bBb) formed on a properdin surface and inhibits the convertase activity of a reconstituted C3bBb complex in solution. The data indicate that albicin specifically recognizes the activated form of the complex, allowing more efficient inhibition by an inhibitor whose quantity is limited.
Share